Cargando…
Enhancing the Therapeutic Efficacy of KRAS(G12C) Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90
BACKGROUND: KRAS(G12C) inhibitors have shown promising efficacy in early clinical trials, but drug resistance compromises their long-term benefits. Therefore, it is critical to understand the mechanisms of drug resistance and to design appropriate combinatory treatments to improve efficacy. METHODS:...
Autores principales: | Liu, Ying, Wu, Lei, Lu, Hong, Wu, En, Ni, Jun, Zhou, Xiaorong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632397/ https://www.ncbi.nlm.nih.gov/pubmed/34858498 http://dx.doi.org/10.1155/2021/2721466 |
Ejemplares similares
-
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
por: Nardi, Francesca, et al.
Publicado: (2023) -
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
por: Azoitei, Ninel, et al.
Publicado: (2012) -
Cotargeting among microRNAs in the brain
por: Cherone, Jennifer M., et al.
Publicado: (2019) -
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015) -
Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma
por: Marrugal, Ángela, et al.
Publicado: (2021)